Domantis' technology is based on antibody fragments.
Phylogica's technology (Phylomers) is based on protein fragments, also known as peptides, which are much smaller and simpler than antibody fragments.
The advantages of phylomers over any type of antibody based technology are that phylomers can be chemically synthesised, they are not subject to antibody royalty stacking, they have more drug delivery possibilities, and can be used for intracellular targets (hence treat more diseases).
All these advantages do not exist for antibody based drugs (whether full antibodies or antibody fragments).
Yes, Domantis and Phylogica operate in a similar space and are to some degree competitors. Domantis is a strong company but it has direct competitors operating in similar technology.
Phylogica's technology is truly unique and in that sense, it has no direct competitors.
When the true efficacy and value of phylomer technology is proven - watch out - this company will be snapped up for a significant sum of money - many multiples of its current market cap imo.
PYC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)